Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Systemic Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Systemic Bio

Systemic Bio

Seed

Systemic Bio leverages 3D technology to create bioprinted organs-on-chips for advanced drug discovery.

HQ
Houston, TX, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize drug discovery and development, Systemic Bio leverages cutting-edge 3D bioprinting technology to create organs-on-chips. These bioprinted models mimic human organ functions, providing a more accurate and efficient platform for preclinical drug testing. Their proprietary platform, built with advanced 3D Systems technology, offers at least 10 times greater build volume and up to 10 times higher resolution than existing commercial technologies, positioning Systemic Bio at the forefront of biomedical innovation.

Systemic Bio boasts a team of leading bioengineering experts dedicated to pushing the boundaries of preclinical drug testing. The company has garnered attention for its state-of-the-art laboratory and significant technological advancements. Notable investors and affiliations include key figures in the biotech and pharmaceutical industries, further validating its impact. Systemic Bio's innovative approach has the potential to significantly reduce the time and cost associated with drug development, making it a pivotal player in the healthcare sector.

Systemic Bio - Quick Facts

When was Systemic Bio founded?

Systemic Bio was founded in 2022.

Where is Systemic Bio's headquarters located?

Systemic Bio's headquarters is located in Houston, TX, US.

When was Systemic Bio's last funding round?

Systemic Bio's most recent funding round was for $15M (USD) in September 2022.

How much has Systemic Bio raised to-date?

As of Sep 15, 2022, Systemic Bio has raised a total of $15M (USD).

How many employees does Systemic Bio have?

Systemic Bio has 11 employees as of Feb 4, 2024.

Systemic Bio - Classification

Ownership
  • Venture Capital
Technology
  • 3d Printing
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Organs-On-Chips
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software